Motilal Oswal Financial Services has recommended a buy on Sun Pharma with a target price of Rs 2,280, citing ongoing efforts in product addition, differentiated clinical development, and branded generics. Sun Pharma reported a 9.29% YoY increase in consolidated total income for Q2 2024 and a net profit of Rs 3030.67 crore. Promoters hold 54.48% stake.
| Subscribe To Our Free Newsletter |
